Why Amylyx is pulling ALS drug Relyvrio from US market after study
Time:2024-05-21 15:28:38 Source:entertainmentViews(143)
WASHINGTON (AP) — The maker of a drug for Lou Gehrig’s disease that recently failed in a large study said Thursday it will pull the medicine from the market, acknowledging it didn’t help patients with the deadly neurological condition.
Amylyx Pharmaceuticals announced it will voluntarily halt sales and marketing of the drug in the U.S. and Canada, where new patients will no longer be able to get a prescription.
“While this is a difficult moment for the ALS community, we reached this path forward in partnership with the stakeholders who will be impacted and in line with our steadfast commitment to people living with ALS,” company co-founders said in a statement. Patients already taking the therapy who wish to continue will be able to enroll in a program to receive it for free.
The Food and Drug Administration approved the much-debated drug, Relyvrio, in September 2022, following a years-long advocacy campaign by patients with amyotrophic lateral sclerosis, or ALS.
Previous:Strictly star Giovanni Pernice's former partner Rose Ayling
Next:Hollywood star Shia LaBeouf is spotted on the streets of Gavin and Stacey's hometown Barry
You may also like
- Six killed in a 'foiled coup' in Congo, the army says
- Legendary CBS announcer Jim Nantz gets tongues wagging on social media after making an X
- Lucy Hale reveals what her current equation is with her Pretty Little Lies co
- Congress PASSES two
- Shooting injures 2 at Missouri high school graduation ceremony
- US carries out first airdrop of aid into Gaza
- Kanye West's ex Julia Fox gives Bianca Censori a run for her money in an X
- Kirsten Dunst says she STILL gets a Christmas cake from Interview With The Vampire co
- Supreme Court declines to hear challenge to Maryland ban on rifles known as assault weapons